Clinical Trials

78 enrolled

Carcinoma, Renal Cell, Neoplasms

NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Phase 2 Suspended

75 enrolled

Carcinoma, Renal Cell

NCT03297606 2026-03-04

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01409200 2026-03-03

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Phase 2 Not yet recruiting

73 enrolled

Lymphatic Metastasis

NCT07123090 2026-02-27

SPARCC

25 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05805501 2026-02-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

199 enrolled

Carcinoma, Renal Cell

NCT05327686 2026-01-14

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT03092856 2025-12-17

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

62 enrolled

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

36 enrolled

Carcinoma, Renal Cell

NCT04996823 2025-12-04

Axitinib + Ipilimumab in Advanced Melanoma

25 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT03595124 2025-12-03

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

15 enrolled 15 charts

Carcinoma, Renal Cell

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

6 enrolled 11 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06962787 2025-11-17

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

260 enrolled

Kidney Neoplasms

NCT07172386 2025-09-16

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

40 enrolled

Carcinoma, Renal Cell

NCT04258956 2025-09-11

AXAGIST

Phase 2 Not yet recruiting

58 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07159191 2025-09-08

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

30 enrolled

Advanced Renal Cell Carcinoma (aRCC)

NCT04341181 2025-07-25

ProTarget

300 enrolled

Tumor-Agnostic

Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

106 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT05969496 2025-04-04

NEOPAX

17 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06889649 2025-03-21

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

30 enrolled

Radiation Therapy

NCT05256472 2025-03-06

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

70 enrolled

Carcinoma, Renal Cell

NCT04562441 2025-01-10

NPC - AXEL Study : Axitinib-Avelumab

13 enrolled

Recurrence

NCT06211114 2024-11-26

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

30 enrolled

Carcinoma, Renal Cell

NCT01693822 2024-11-21

A-PREDICT

65 enrolled 15 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02639182 2024-11-18

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

133 enrolled 35 charts

Carcinoma, Renal Cell

NCT01263769 2024-09-19

Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

39 enrolled 6 charts

Kidney Neoplasms

NCT02636725 2024-07-12

Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

33 enrolled 14 charts

Sarcoma

Sarcoma, Sarcoma, Alveolar Soft Part

NCT05420220 2024-05-01

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

54 enrolled

Thoracic

Advanced Non-small Cell Lung Cancer

NCT03472560 2024-04-09

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

61 enrolled 26 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT02579811 2023-06-29

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

40 enrolled 12 charts

Carcinoma, Renal Cell, Neoplasms

NCT05817903 2023-05-08

AxIn

118 enrolled

Carcinoma, Renal Cell

NCT05249569 2023-05-03

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

1 enrolled 4 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04010071 2023-03-29

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

60 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms

NCT01385059 2023-03-07

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

11 enrolled 10 charts

Prostatic Neoplasms

NCT02489695 2022-09-06

AXIPAP

44 enrolled

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT05263609 2022-08-02

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

Phase 2 Withdrawn

Carcinoma, Renal Cell

NCT02129647 2021-12-01

Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

13 enrolled 7 charts

CNS

Neuroma, Acoustic, Neurofibromatosis 2

NCT02261207 2021-09-28

Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor

17 enrolled

Solitary Fibrous Tumors

NCT01649180 2021-08-12

PrE0801

3 enrolled 7 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04995016 2021-08-06

PANDORA

18 enrolled

Carcinoma, Renal Cell

NCT04958473 2021-07-12

SAARCC

40 enrolled

Carcinoma, Renal Cell

NCT03494816 2021-06-30

NAXIVA

24 enrolled 11 charts

Carcinoma, Renal Cell

NCT02762513 2021-05-05

Expansion Trial for Axitinib In Head And Neck Cancer

29 enrolled 18 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01140737 2021-03-18

Axi-STS

145 enrolled

Sarcoma

NCT01321437 2021-01-20

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

11 enrolled 12 charts

Dermatologic

Melanoma

NCT01967576 2021-01-06

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

14 enrolled 12 charts

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04698213 2021-01-06

TIDE-A

75 enrolled

Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT01798446 2020-12-08

A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

41 enrolled

Carcinoma, Renal Cell

NCT04197219 2020-11-05

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

Phase 2 Withdrawn

Gynecologic

Endometrial Neoplasms

NCT04459663 2020-07-07

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.